End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
49.75 CNY | +5.72% | +14.55% | -7.65% |
Apr. 18 | Sinocelltech Forecasts Return to Profit in Q1 | MT |
Apr. 18 | China stocks track Asian markets higher | RE |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 78.97 times its estimated earnings per share for the ongoing year.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.65% | 3.06B | - | ||
-2.31% | 103B | B+ | ||
+0.56% | 95.28B | B+ | ||
+0.29% | 22.15B | B | ||
-17.37% | 21.02B | B+ | ||
-8.79% | 18.15B | A- | ||
-41.01% | 16.73B | A- | ||
-14.85% | 16.05B | B | ||
+3.21% | 13.68B | C+ | ||
+33.54% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688520 Stock
- Ratings Sinocelltech Group Limited